TNFRSF18 and neoplasm: Treatment of the host mice with an agonist anti-GITR mAb DTA-1 (0.5 mg, i.p.)resulted in ∼50% reduction in tumour foci in the lungs, as compared with control IgG-treated mice (Fig. 8b).